September 10, 2025Annals of Surgical OncologyOpen Access

Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?

View Full Paper

Ask AI

Bookmark

Overall recurrence-free survival (RFS) rate was found to be 69% within two years, indicating significant outcomes for patients.
Pre-surgical lymphovascular invasion increased the risk of recurrence, with a hazard ratio of 1.764, highlighting critical prognostic factors.
This single-institution retrospective cohort study included 229 patients diagnosed with clinical stage IIB/IIC melanoma from 2006 to 2019.
Findings may help optimize patient selection for neoadjuvant immunotherapy in clinical stage IIB/IIC melanoma management.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study identified recurrence rates and survival outcomes in patients with clinical stage IIB/IIC melanoma, suggesting key factors for therapy consideration.

Cite This Study

Farooq et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d647860d9 https://doi.org/10.1245/s10434-025-18263-z

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study identified recurrence rates and survival outcomes in patients with clinical stage IIB/IIC melanoma, suggesting key factors for therapy consideration.

Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?

Key Points

Discussion

Implication

Cite This Study

Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading